It must be stressed, however, that although biologics targeting IL-1β, TNF-α, and the IL-23/IL-17 axis have shown efficacy in systemic inflammatory diseases and in experimental periodontitis models (Table 3), randomized controlled trials in periodontal patients are still scarce (for a list of currently registered clinical trials see Supplementary Table S1). Here, IL17A is linked to periodontitis.